segunda-feira, 28 de setembro de 2026
PesquisarExplore
pt.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 19, 2026

FDA approves Novo Nordisk's new Wegovy® HD injection, delivering the highest weight loss to date for a Wegovy® injection, adding to its already expansive clinical profile

View original at finance.yahoo.com
FDA approves Novo Nordisk's new Wegovy® HD injection, delivering the highest weight loss to date for a Wegovy® injection, adding to its already expansive clinical profile Average weight loss of ~21% at 72 weeks in adults with obesity if all patients stayed on treatment* with Wegovy® HD (~19% regardless of whether patie…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Wegovy is the only GLP-1 for adults with obesity proven to reduce the risk of events such as stroke, heart attack, or cardiovascular death in those with known heart disease

    60% confidence

  • The weight loss demonstrated with Wegovy HD could reshape healthcare professionals' expectations about what outcomes are possible for patients with Wegovy

    60% confidence

  • Wegovy HD represents an important new tool in obesity management that allows clinicians to better tailor treatment strategies and improve outcomes

    60% confidence

  • No other weight loss medicine has been studied to show superiority to Wegovy HD

    60% confidence

  • Obesity is a serious, chronic, progressive, and complex disease requiring long-term management, not just a disease of lack of willpower

    60% confidence

Data points we hold from this source

Novo Nordisk · pharmacy distribution network70000 pharmacies
Novo Nordisk · us facilities10 locations
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Vertical AI Agents Attract a Funding Wave Across Fintech-Adjacent Industries
A cluster of AI-native startups applying autonomous agents to narrow, operational problems — hotel front-desk staffing (Dextr AI), identity/fraud risk for financial institutions (Baselayer), insurance distribution (Napo, Connie Health, MGT Insurance) — closed seed-to-Series A rounds within days of each other in September 2026, with CB Insights running a coordinated CEO interview series to spotlight them. The pattern points to agentic AI maturing from generic chat tools into vertical, revenue-generating products, with identity verification for AI agents themselves (Baselayer) emerging as a new fintech infrastructure category responding directly to AI-driven fraud risk.
A nossa leitura dos dados ›
Sinais que acompanhamos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Padrões que observamos ›
Onde as fontes divergem
Berkshire Hathaway
Both facts report Berkshire Hathaway's cash position on 2026-01-01 with identical observation timestamps, but claim vastly different values: 380 billion USD vs 400 USD. These cannot both be true for the same entity at the same point in time. The magnitude of the discrepancy (a factor of ~10^9) rules out rounding, unit conversion, or methodological differences.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,984
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,984 factos verificados com a fonte5,306 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
FDA approves Novo Nordisk's new Wegovy® HD injection, delivering the highest weight loss to date for a Wegovy® injection, adding to its already expansive clinical profile — Source | Via News | pt.VIA.NEWS